Chemoradiotherapy plus immunotherapy for first-line bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) can help people with intrahepatic bile duct cancer that hasn't been treated before. It aims to see if this triple approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with intrahepatic bile duct cancer (confirmed by biopsy).
- You have not received any previous treatment for this cancer.
- Your liver function is good (Child-Pugh class A) and your blood counts are within certain ranges.
- You are between 18 and 75 years old.
- You have not had radiation therapy before.
- You are willing to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy for people with advanced bile duct cancer that has not been treated before. The goal is to see if this new approach can help shrink tumors or slow their growth.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
This trial tests a combination of radiation therapy (SBRT), two chemotherapy drugs (gemcitabine and cisplatin), and an immunotherapy drug (sintilimab) as a first-line treatment for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
Hear when a new ICC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.